Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398383 · ClinicalTrials.gov registry record · Early Phase 1
Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02398383: Completed Early Phase 1 study, sponsored by Yale University.
NCT02398383 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02398383, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance. Cystic fibrosis patients with normal glucose tolerance as well as cystic fibrosis related diabetes as well as control subjects will undergo an oral glucose tolerance test, mixed meal tolerance test, and one step hypoglycemic clamp. Cystic fibrosis patients will then return 12 months later to undergo repeat mixed meal tolerance test and hypoglycemic clamp test.
Primary Outcome
Glucagon levels in response to to a mixed meal stimulus
Interventions
- OTHER Oral Glucose Tolerance Test
- OTHER Mixed Meal Tolerance Test
- OTHER Hypoglycemic Clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06-22 |
| Phase | Early Phase 1 |
What the finished NCT02398383 record still lists
NCT02398383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Oral Glucose Tolerance Test is the first listed.
NCT02398383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02398383 about?
NCT02398383 is a clinical study titled "Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes". This project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance. Cystic fibrosis patients with normal glucose tolerance as well as cystic fibrosis related diabetes as well as control s...
What is the current status of trial NCT02398383?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2015-03. Estimated completion is 2017-06-22.
What interventions are being tested in trial NCT02398383?
The interventions under investigation include: Oral Glucose Tolerance Test (OTHER), Mixed Meal Tolerance Test (OTHER), Hypoglycemic Clamp (OTHER).
Who is sponsoring clinical trial NCT02398383?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02398383's enrollment target sits among peer trials
7 1826th of 2000 higher than 156 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia